ADMA

ADMA Biologics, Inc. (ADMA) ESG Analysis Analysis (2026)

Invetso Score: 6.4/10 — Balanced · Last Updated: 2026-08-01

Environmental

ADMA’s low R&D intensity versus revenue suggests a relatively light direct environmental footprint, but this metric is less informative than peers’ manufacturing and supply-chain exposures.

The company’s capital structure appears modestly leveraged, which can constrain environmental investment flexibility relative to stronger-balance-sheet peers in regulated healthcare manufacturing.

No Tier 1 evidence provided indicates material environmental controversies, so the main peer comparison is a neutral-to-slightly-better operational footprint rather than a clear sustainability lead.

Because ADMA’s business is biologics-focused rather than heavy industrial, its environmental risk profile is structurally lower than peers with energy-intensive production, though not best-in-class.

Social

ADMA’s biologics operations make product quality and patient safety central social factors, but the provided data do not show peer-leading disclosure or independently verified outcomes.

The company’s relatively high gross margin can support workforce investment and quality systems, yet this is an indirect social signal rather than a disclosed labor advantage.

Stock-based compensation is moderate versus revenue, suggesting compensation practices are not obviously misaligned, though peer comparison remains limited without broader disclosure.

Absent reported controversies in the supplied sources, ADMA appears broadly in line with peers on social risk, but not clearly stronger on transparency or stakeholder management.

Governance

ADMA’s debt-to-equity and net-debt-to-EBITDA ratios indicate manageable leverage, which supports governance resilience relative to more financially constrained peers.

Stock-based compensation at a moderate level suggests dilution risk is present but not extreme, leaving governance quality broadly acceptable versus peers.

The absence of provided filing-based evidence on board independence, audit issues, or shareholder rights limits confidence in a stronger governance assessment.

Overall governance appears adequate rather than leading, with no clear structural red flags but also no disclosed controls or policies that distinguish it from peers.

Overall Score

ADMA’s ESG positioning is broadly average versus peers, with relatively contained environmental and governance risk but limited evidence of standout disclosure or leadership.

Score Driver: The Decisive Factor Is A Generally Neutral Peer-Relative Risk Profile Without Major Controversies Or Clear ESG Leadership Signals.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on ADMA Biologics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →